Prosecution Insights
Last updated: August 16, 2026
Application No. 17/335,680

Method for the reduction of host cell proteins in affinity chromatography

Non-Final OA §112
Filed
Jun 01, 2021
Priority
Aug 21, 2015 — EU 15181903.4 +2 more
Examiner
KIM, YUNSOO
Art Unit
1641
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hoffmann-La Roche Inc.
OA Round
5 (Non-Final)
66%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
616 granted / 936 resolved
+5.8% vs TC avg
Strong +35% interview lift
Without
With
+34.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
59 currently pending
Career history
992
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
37.7%
-2.3% vs TC avg
§102
16.3%
-23.7% vs TC avg
§112
22.0%
-18.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 936 resolved cases

Office Action

§112
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/20/26 has been entered. 3. Claims 1, 3, 5, 7 and 9-16 are pending upon entry of amendment filed on 5/20/26. Claims 1-5, 7 and 9-16 are under consideration in the instant application. 4. In light of Applicant’s amendment to the claims, the rejection of record has been withdrawn. 5. The following new ground of rejection is necessitated by Applicants’ amendment filed on 5/20/26. 6. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. 7. Claims 1, 3, 5, 7 and 9-16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a New Matter rejection. The specification or the original claims as filed does not provide a written description the phrases “about 50mM to about 1000mM histidine” and “about 100mM to about 1500mM Tris”. Applicants assert that the currently added limitation is found from the specification in p. 8-9 of the specification of the instant application. The specification supports for about 10mM to about 1000mM of histidine, or 50mM to about 400mM of histidine at most in p. 8-9. However, the specification does not support 50mM to about 1000mM of histidine as currently amended. No exemplary formulations that are encompassed by the currently amended claims such as 10mM to about 1000mM of histidine, or 50mM to about 400mM of histidine with 100mM to about 1500mM TRIs in the context with amended claims are present in the specification. The currently amended range is not supported by the original claims or instant specification. The instant claims now recite a limitation which was not clearly disclosed in the specification as filed, and now changes the scope of instant disclosure as filed. Such limitations recited in the present claims, which did not appear in the specification as filed, introduce new concepts and violate the description requirement of the first paragraph of 35 U.S.C.112. 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to YUNSOO KIM whose telephone number is (571)272-3176. The examiner can normally be reached on Mon-Fri 8:30-5. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Misook Yu can be reached on 571-272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Yunsoo Kim Patent Examiner Technology Center 1600 July 27, 2026 /YUNSOO KIM/Primary Examiner, Art Unit 1641
Read full office action

Prosecution Timeline

Show 6 earlier events
Aug 01, 2025
Request for Continued Examination
Aug 04, 2025
Response after Non-Final Action
Oct 14, 2025
Non-Final Rejection mailed — §112
Jan 13, 2026
Response Filed
Feb 20, 2026
Final Rejection mailed — §112
May 20, 2026
Request for Continued Examination
May 21, 2026
Response after Non-Final Action
Jul 30, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12703751
CANINIZED RAT ANTIBODIES TO CANINE INTERLEUKIN-31 RECEPTOR ALPHA
3y 4m to grant Granted Aug 11, 2026
Patent 12668619
METHOD OF IMPROVING BLOOD KINETICS OF PEPTIDE
5y 1m to grant Granted Jun 30, 2026
Patent 12668609
Methods and Devices for the Enrichment of Immunoglobulin from Blood
4y 6m to grant Granted Jun 30, 2026
Patent 12662523
PHARMACEUTICAL FORMULATIONS CONTAINING CD80 EXTRACELLULAR DOMAIN-FC FUSION PROTEINS
4y 7m to grant Granted Jun 23, 2026
Patent 12662529
Production of Biosimilar Ustekinumab In CHO Cells
1y 4m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+34.8%)
3y 7m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 936 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month